Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Protection against Rotavirus Disease after Natural Rotavirus Infection

Richard L. Ward, David I. Bernstein and US Rotavirus Vaccine Efficacy Group
The Journal of Infectious Diseases
Vol. 169, No. 4 (Apr., 1994), pp. 900-904
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30113851
Page Count: 5
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Protection against Rotavirus Disease after Natural Rotavirus Infection
Preview not available

Abstract

Determination of protective efficacy after natural rotavirus infection is important as a basis for evaluating rotavirus vaccines. Therefore, placebo recipients in a large 2-year rotavirus vaccine trial conducted across the United States were followed to determine the protection afforded by natural rotavirus infection. Serotype 1 rotaviruses predominated (93% year 1, 66% year 2), but isolates of all four major human rotavirus serotypes circulated during both years. Of the 45 placebo recipients with documented rotavirus illnesses in year 1,1 developed rotavirus disease in year 2 compared with 29 of the other 235 placebo recipients (P = .03). Serologic data were available for 171 placebo recipients, and 37 of 140 without rotavirus illnesses in year 1 had evidence of asymptomatic rotavirus infection. None of these 37 experienced rotavirus disease in year 2 compared with 22 of the remaining 103 (p <.001). Overall efficacy after natural rotavirus infection was 93% (95% confidence interval, 50%-99%).

Page Thumbnails

  • Thumbnail: Page 
900
    900
  • Thumbnail: Page 
901
    901
  • Thumbnail: Page 
902
    902
  • Thumbnail: Page 
903
    903
  • Thumbnail: Page 
904
    904